BAYN.DE is trading 2.8% up today at $47.97 after a U.S. Supreme Court decision to scale back Roundup cancer lawsuits in the company's favor.

  • The ruling significantly reduces litigation risk and improves visibility on potential settlement costs, addressing a major long-term headwind.
  • The favorable legal development supports recent analyst optimism and higher price targets, driving a broader surge in the shares.